Butyrate, an HDAC inhibitor, modulates leukocyte activation, innate immune response, and oxidative stress to inhibit neutrophil migration capacity, formation of NETs, and secretion of pro-inflammatory cytokines in inflammatory bowel disease (IBD), thereby improving IBD [204]. This evidence concerns the gene HDAC9 and inflammatory bowel disease.